SinoBiomed (SOBM) just announced the completion of Phase II-A clinical trials on its proprietary drug for the treatment of surgical bleeding. SinoBiomed is headquartered in the center of the modern virus-plague capital of the world: China. Earlier this year, the company obtained patent-protection in both the American and European markets for the development of its groundbreaking malaria vaccine.

SinoBiomed has the profile of a company that can make the successful transition to an upper exchange listing such as the American Stock Exchange (Amex). My call is that a select group of Wall Street institutions are already aware that SinoBiomed is a top biotech stock-buy based on profit probabilities – yet they must wait until the company moves up from the bulletin-board exchange to the Amex before taking a substantial position. Look for SinoBiomed to complete an upward transition to the Amex within the next two business quarters.

<< BACK TO HOME PAGE | ARCHIVES >>